According to Tang, this independence suggests that each biomarker provides unique prognostic information, making both valuable for understanding patient outcomes. Building on these findings, the ...

Time to first symptomatic skeletal event, whether including or excluding death, was similar between treatment arms. Most patients did not experience skeletal complications during the follow-up period.

The phase 3 IMvigor011 (NCT04660344) 1 trial, presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, represents a landmark shift toward perso ...

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...

At the 2026 ASCO Genitourinary Cancers Symposium, Dr. Andrea Necchi shared the final results of the SunRISe-2 phase 3 trial, ...

Antonio Ocejo, MD, discussed a multi-institutional analysis focusing on the clinical outcomes and tolerability of ipilimumab ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines. Patients with relapsed/refractory ...

“Incorporating ctDNA into the decision-making process helps refine who can safely keep their bladder,” Ghatalia, associate professor, Department of Hematology/Oncology, at Fox Chase Cancer Center in ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

Divergence in the post-progression interval suggests disparities may concentrate in subsequent-line therapy, surveillance, supportive care, or access to timely interventions outside trial ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.